Xenon Pharmaceuticals Inc (XENE)
Health Care · Biotechnology · NASDAQ
A clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapies for the treatment of neurological disorders.
Price as of 2026-10-29 close.
- Market cap
- $3.6B
- Next earnings
- Nov 2, 2026 (confirmed)
| 3M | 6M | 1Y | |
|---|---|---|---|
| XENE | -40.5% | -32.7% | -11.3% |
| S&P 500 (SPY) | +5.5% | +8.1% | +11.9% |
Informational only — not financial advice.
Long-term picture
| Business quality | 3/10 | below average | vs covered US companies |
|---|---|---|---|
| Price vs fundamentals | 6/10 | middle of the pack | vs covered US companies |
| Long-run trend | 2/10 | weak | vs covered US companies |
| Cash returned to shareholders | 3/10 | below average | vs covered US companies |
A below-average business at a price in the middle of the field. The long-run trend is down. This reads published data; it is not a recommendation.
Is the price reasonable?
Not enough fiscal-year history to compare today's multiples with its own past.
Free cash flow is negative, so the price cannot be read this way.
As of 2026-10-29. How this is computed.
What would change this picture
- Debt to equity is 0, which is strong for covered US companies (percentile 94.9).
- The price is 28.2% below its 200-day average.
- Next results 2026-11-02 (confirmed); analysts expect EPS between $-1.29 and $-0.94.
- Risks the company itself lists in its latest filing.
Scores come from the published Top 10 method, as of 2026-10-29; technical indicators as of 2026-10-29; analyst estimates as of 2026-10-21. See what this is.
What Xenon Pharmaceuticals Inc does
Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for neurological disorders. The company's primary research and development efforts are dedicated to advancing its pipeline of product candidates, with a lead focus on azetukalner for various indications.
Themes: neurological disorders, small-molecule drugs
Fundamentals
- Price$37.54
- Market cap$3.6B as of 2026-08-03 (share count; price 2026-10-29)
- 1-year return-11.3% 2025-10-29 close $42.30 → 2026-10-29 close $37.54
- P/En/a negative earnings
- ROE-59.5%
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equity0.00 0 — no debt reported (no debt lines tagged in its filing) — 10-Q/10-K balance sheet 2026-06-30
- Revenue CAGR (3y)-77.8%
- Beta0.94
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
Sources and dates — Price: as of 2026-10-29 close · ROE: FY2025, SEC XBRL · Revenue CAGR (3y): SEC XBRL · Beta: as of 2026-09-02
How XENE compares in its sector
- return on equity-59.5% · bottom 25% median -23.0%
- 3-year revenue CAGR-77.8% · bottom 10% median 10.5%
- free cash flow (absolute dollars, latest fiscal year)$-279.9M · bottom 10% median $-25.0M
Dot: where it sits among covered Health Care peers (0 = lowest value, 100 = highest); tick: the sector median.
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better").
Top 10 scores & list membership
XENE is not currently in any published Top 10 list. Its scores are below.
Top 10 score
28.3 #1287 of 1,308 scored · #150 of 155 in Health Care
Financial health 95th (debt to equity 0 (no debt reported)) and valuation 56th (price to book 2.9); weakest is growth (1st, 3-year revenue CAGR -77.8%).
Scores as of 29 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Quarterly results
Reported annual figures from the company's 10-K filings (SEC XBRL); actuals only, no estimates.
| Quarter | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|
| Q2 FY26 2026-06-30 | -$123M | -$111M | -$1.11 | -$95M† | $275000† |
| Q1 FY26 2026-03-31 | -$112M | -$102M | -$1.17 | -$89M | $133000 |
| Q4 FY25 2025-12-31 | -$110M† | -$105M† | -$1.31† | -$81M† | $318000† |
| Q3 FY25 2025-09-30 | -$96M | -$91M | -$1.15 | -$72M† | $281000† |
| Q2 FY25 2025-06-30 | -$94M | -$85M | -$1.07 | -$64M† | $157000† |
| Q1 FY25 2025-03-31 | -$73M | -$65M | -$0.83 | -$62M | $43000 |
| Q4 FY24 2024-12-31 | -$77M† | -$66M† | -$0.84† | -$54M† | $783000† |
| Q3 FY24 2024-09-30 | -$74M | -$63M | -$0.81 | -$50M† | $590000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$120M
- Short-term investments$811M
- Total debt0 — no debt reported as of 2026-06-30
- Net debt-$931M no debt reported − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed.
How Xenon Pharmaceuticals Inc looks technically
Xenon Pharmaceuticals Inc (XENE) is trading 28.2% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 13 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 42, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 45, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 10 trading days ago. It is 48.3% below its highest point of the past year.
Trend
7
| Distance from the 200-day | What it meansit is trading 28.2% below its 200-day average, the long-term trend line — a long-term downtrend | -28.2% |
|---|---|---|
| 50-day moving average | What it meansits average price over the last 50 trading days — a short-term trend line — is $45.79 | $45.79 |
| 200-day moving average | What it meansits average price over the last 200 trading days — the long-term trend line — is $52.27 | $52.27 |
| Swing structure | What it meanseach recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | What it meansits last significant turn was a swing high 8 calendar days ago — the swings before that are what the structure reading is measured on | 8 sessions |
| Since the 50/200 cross | What it meansits 50-day average crossed below its 200-day average about 13 trading days ago — a "death cross", a bearish long-term signal | 13 sessions |
| Trend strength (14-day ADX) | What it meansa strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 42, with sellers in control | 41.5 |
Momentum
3
| 14-day RSI | What it meansmomentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 45, neither overbought (above 70) nor oversold (below 30) | 44.8 |
|---|---|---|
| Position in its 14-day range | What it meansit is trading right at the top of its 14-day range ($33.38 to $37.69) — its "stochastic" reading is 97 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 96.6 |
| Since the MACD crossed zero | What it meansMACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 17 sessions |
Range
12
| 52-week high | What it meansits highest closing price over the past year (about 252 trading days) was $72.66 | $72.66 |
|---|---|---|
| From the 52-week high | What it meansit is 48.3% below its 52-week high (its highest price of the past year) | -48.3% |
| Above the 52-week low | What it meansit is 12.5% above its 52-week low (its lowest price of the past year) | +12.5% |
| Below the 52-week high | What it meansit is 48.3% below its highest point of the past year | 48.3% |
| Since a 20-day breakout | What it meansit made a new 20-day low about 10 trading days ago | 10 sessions |
| Since a 55-day breakout | What it meansit made a new 55-day low about 10 trading days ago | 10 sessions |
| All-time high | What it meansits highest closing price on record is $72.66 (set on 2026-07-09) | $72.66 |
| Given back of the 52-week move | What it meansover the past year its closes ranged ($33.49 to $70.96), and it has recovered only a small part of its fall from last year’s high — 11% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $56.65 to $57.85. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 10.8% |
| From the all-time high | What it meansit is 48.3% below its all-time high | -48.3% |
| Nearest price level | What it meansit is trading 0.7% above a support level at $37.28 — a price it turned at six times since 2024-11-18, most recently on 2026-10-21. Since 2024-10-29 it has 4 such levels below the current price and 10 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.7% |
| All-time low | What it meansits lowest closing price on record is $2.10 (set on 2017-11-16) | $2.10 |
| Above the all-time low | What it meansit is 1687.6% above its all-time low | +1,688% |
Volatility
5
| Band width vs its own 6 months | What it meansday-to-day price swings are about average versus its own recent 6-month history | 54th percentile |
|---|---|---|
| Typical daily range | What it meansin a typical session it travels about $1.48 between its high and its low — about 3.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.48 |
| Bollinger bands (20-day, ±2σ) | What it meansmost of its recent trading has stayed between about $33.56 and $38.23 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $33.56 – $35.90 – $38.23 |
| Typical daily range (% of price) | What it meansits price moves about 3.9% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.9% |
| Stretch from the 200-day average | What it meansit is trading 10.0 daily ranges below its 200-day average price (28.2% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 10.0 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | What it meanstrading volume is about normal versus its 30-day average | 0.63× |
|---|
Analyst
2
| Change in the average price target | What it meansanalysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | What it meansthe analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bearish engulfing | What it means4 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 4 sessions ago |
|---|
Price gaps
3
| Gap at the open | What it meansit opened on 2026-10-29 2.6% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +2.6% |
|---|---|---|
| Open gap | What it meansit gapped 2.6% above the previous close today and has not traded back through the level it left behind at 36.34 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.6% |
| Gap filled | What it meansa 3.0% gap up opened on 2026-10-01 has been "filled" 18 sessions ago — price traded back through the level the gap left behind, and it took 2 sessions to close | 18 sessions ago |
Price streaks
1
| Closing streak | What it meansit has closed higher 4 sessions in a row, a +6.23% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 4 sessions up |
|---|
Relative strength
4
| vs market, 1 month | What it meansover the past 1 month this stock beat the market by 0.1 percentage points (the stock gained 0.8% while the market gained 0.7%) | +0.1% |
|---|---|---|
| vs market, 3 months | What it meansover the past 3 months this stock lagged the market by 46.0 percentage points (the stock lost 40.5% while the market gained 5.5%) | -46.0% |
| vs market, 6 months | What it meansover the past 6 months this stock lagged the market by 40.8 percentage points (the stock lost 32.7% while the market gained 8.1%) | -40.8% |
| vs market, 12 months | What it meansover the past 12 months this stock lagged the market by 23.2 percentage points (the stock lost 11.3% while the market gained 11.9%) | -23.2% |
Signal agreement
2
| Bullish technical signals | What it means1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | What it means6 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a strong downtrend, with sellers in control, lagging the market over 6 months, near the top of its 14-day range (overbought), trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | What it meanstrading 24% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-23 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 9.5% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -23.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | What it meansthe price is 26% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $50.85 — a volume-weighted average of daily closes over 206 sessions, not a true tick-by-tick VWAP. | -26.2% |
|---|---|---|
| Vs the average paid since it last reported | What it meansthe price is 12% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $42.63 — a volume-weighted average of daily closes over 60 sessions, not a true tick-by-tick VWAP. | -11.9% |
Price levels it has turned at before
XENE last closed at $37.54 on 2026-10-29. Since 2024-10-29 it has turned at 4 prices below its last close and 10 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $37.28 | Support | 0.7% below the last close | turned there six times · 2024-11-18 to 2026-10-21 |
| $38.06 | Resistance | 1.4% above the last close | turned there three times · 2025-01-23 to 2025-09-17 |
| $39.24 | Resistance | 4.5% above the last close | turned there four times · 2025-05-01 to 2026-01-20 |
| $35.78 | Support | 4.7% below the last close | turned there twice · 2025-09-15 to 2025-09-25 |
| $40.26 | Resistance | 7.2% above the last close | turned there five times · 2025-09-03 to 2026-10-01 |
| $33.55 | Support | 10.6% below the last close | turned there five times · 2025-02-28 to 2026-10-16 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-29.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Recent death cross (50-day crossed below 200-day) · Pulled back from the 12-month high · lagging the market · Stretched far below its 200-day average (6+ daily ranges) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-29. Describes past price behavior only.
Analyst consensus
- Consensus ratingStrong Buy (1.26 mean, 1=Strong Buy…5=Strong Sell) — 18 analysts
- Mean price target$72.43 range $46.00 – $90.00; median $73.50
Analyst estimates, as of 2026-10-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm.
Analyst EPS estimate for XENE
- Consensus EPS estimate-$1.15 next reporting period, as of 2026-10-21
- Estimate change, 30 days+$0.00154 from -$1.15, on 2026-09-16, 35-day window
- Readings revised upward30% of 10 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. It is not a forecast.
Key risks (from latest filing)
- History of significant operating losses and no commercial revenue to date.
- High risk of clinical trial failure and inability to obtain regulatory approval for product candidates.
- Need for substantial additional capital and potential dilution of shareholders to fund ongoing R&D and commercialization efforts.
What changed in the latest 10-Q
AI-assisted comparison of XENE's 10-Q filed 2026-05-07 against the prior one filed 2025-11-03.
- Risk Factors · Reworded: Net loss figures updated from '$240.6 million and $168.6 million for the nine months ended September 30, 2025 and 2024' (filed 2025-11-03) to '$102.3 million and $65.0 million for the three months ended March 31, 2026 and 2025' (filed 2026-05-07)
- Risk Factors · Reworded: Accumulated deficit updated from '$1,140.1 million as of September 30, 2025' (filed 2025-11-03) to '$1,347.7 million as of March 31, 2026' (filed 2026-05-07)
- Risk Factors · Reworded: Page number changed from '- 24 -' (filed 2025-11-03) to '- 25 -' (filed 2026-05-07)
Show all
Risk Factors
- Reworded:
- Net loss figures updated from '$240.6 million and $168.6 million for the nine months ended September 30, 2025 and 2024' (filed 2025-11-03) to '$102.3 million and $65.0 million for the three months ended March 31, 2026 and 2025' (filed 2026-05-07)
- Accumulated deficit updated from '$1,140.1 million as of September 30, 2025' (filed 2025-11-03) to '$1,347.7 million as of March 31, 2026' (filed 2026-05-07)
- Page number changed from '- 24 -' (filed 2025-11-03) to '- 25 -' (filed 2026-05-07)
- Notes:
- Financial figures reflect different reporting periods (nine months vs. three months) so are not directly comparable on a per-period basis
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only and makes no materiality, legal, or investment judgement.
Insider activity (SEC Form 4)
2 open-market purchases and 3 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-25. The 6 days since 2026-10-25 have not been checked yet.
- Last 90 days · read to 2026-10-252 buys ($2M) · 3 sells ($1M) — 2 buying, 2 selling insiders
- Last 180 days · read to 2026-10-252 buys ($2M) · 5 sells ($1M) — 2 buying, 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-30. Based on Form 4 filings read through 2026-10-25; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about XENE's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy.
Institutional ownership (13F)
5 of the 10 institutional managers we track reported holding XENE (13F, quarter ended 2026-06-30; a quarter-end position filed within 45 days, not every institution that holds it).
- Tracked 13F managers holding it 5 of 10
- Reported shares held 22.2M
- Reported value $1.3B
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade.
Ask about XENE's institutional holders → See what each manager we track holds →
Short interest (FINRA)
XENE had 6,041,487 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
XENE had 6.24% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 1.58 days to cover at the same settlement.
- Reported short interest (shares) 6.0M
- Short interest (% of shares outstanding) 6.24%
- Prior settlement (shares) 6.4M
- Reported change -6.26%
- Days to cover (reported) 1.58
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float.
Frequently asked questions
What does Xenon Pharmaceuticals Inc (XENE) do?
Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for neurological disorders. The company's primary research and development efforts are dedicated to advancing its pipeline of product candidates, with a lead focus on azetukalner for various indications.
What sector is Xenon Pharmaceuticals Inc (XENE) in?
Xenon Pharmaceuticals Inc (XENE) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Is Xenon Pharmaceuticals Inc (XENE) overbought or oversold right now?
Xenon Pharmaceuticals Inc (XENE) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 45, in the neutral middle (as of 2026-10-29). RSI describes recent price momentum, not a forecast.
Where does stocks-llm's data on XENE come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-29.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.